Thanks. It's a very good list. There are a couple that stand out for me. There is current work on this committee around marketing to kids and a national child and youth commissioner—that one is spoken about on this committee, around health care for children, as well. Thank you for underscoring them. I would say it's a very comprehensive list of suggestions.
I'll move on to Dr. McLaughlin.
We talked a bit about rare diseases. February 28 was the rare disease advocacy day. I used to participate with a friend named Simon Ibell, who started something called “Be Fair 2 Rare”, and it got me thinking more about rare disease advocacy prior to becoming a politician. I think I've mentioned him before on this committee. He was a special guy who left us too soon. His work was exceptional.
I'm wondering to what degree you've been engaged in Canada's rare disease strategy and rare disease drug strategy. I spoke at the CORD conference last year. I had an opportunity to hear from advocates directly. They mentioned that work is ongoing, but it's complicated, obviously, because it's so far-reaching.
Do you have any comments on Canada's future rare disease strategy, as it pertains to drugs or treatment?